Overview

A Phase 3 Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment With AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Status:
Not yet recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the monotherapy in essential hypertensive subjects who are not adequately controlled on AZM and AML monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Celltrion